Figure 3From: Biomarkers can predict potential clinical responders to DIMS0150 a toll-like receptor 9 agonist in ulcerative colitis patients Design of the explorative phase IIa study. Steroid resistant and steroid dependent UC patients were included in a placebo controlled double-blind study to re-affirm the target group for the treatment with DIMS0150 and for evaluation of biomarkers. (Black arrow) efficacy measure time point, (dashed arrow) follow-up time point.Back to article page